Enumeral Biomedical (ENUM) Expands Scientific Advisory Board To Support Development Of Novel Immunomodulators

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tumor biology and cancer immunotherapy. Enumeral is applying its proprietary immune profiling technology to enable the development of potential best-in-class antibodies against targets in immuno-oncology and other disease applications. The Company's lead program is focused on a next-generation PD-1 antibody, which is expected to enter clinical testing in 2016.

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.